Genomica SAU (Zeltia) has achieved another step in its internationalisation process by establishing, as of 17th January 2013, its Scandinavian (Denmark, Sweden and Norway) subsidiary, Genomica AB.
Based in Lund, Sweden, Genomica AB intends to support the Scandinavian market, due to its strategic importance and also for its high growth potential. Genomica began its international expansion in 2006, focusing initially on the European market. In 2007, the company expanded its market to countries in Central and South America. Currently, Genomica is present in more than 35 countries worldwide and is actively continuing its global expansion.
Founded in 1990, Genomica is based in the Madrid region of Spain. Wholly-owned by Zeltia, the company's main goal is to lead the Spanish market in genomic applications, and expand internationally in the area of molecular diagnostics and personalised medicine by designing, developing and selling new diagnostic applications based on the CLART (clinical array technology) platform. Genomica has developed a diagnostic test for HPV (associated with cervical cancer), a system for diagnosing respiratory viruses and a method for detecting human herpes virus; it also markets a test for detecting genetic markers associated with response to therapy.